In New Zealand, it is recommended that all pregnant women have a haemoglobin A1c (HbA1c) test performed with their booking antenatal bloods, ideally before 20 weeks' gestation, to identify those with previously unrecognised diabetes (≥50 mmol/mol), as well as women with lesser degrees of hyperglycaemia.
INTRODUCTION
In New Zealand, it is recommended that all pregnant women have a haemoglobin A1c (HbA1c) test performed with their booking antenatal bloods, ideally before 20 weeks' gestation, to identify those with previously unrecognised diabetes (≥50 mmol/mol), as well as women with lesser degrees of hyperglycaemia. 1 However, not all women have booking antenatal bloods. For example, a Christchurch study found that 17% of women did not have booking antenatal blood tests prior to delivery, and this rate is even higher among Māori DOI: 10.1111/ajo.12786 lished data on the analytical performance of the COBAS b101 point-of-care system in testing HbA1c in pregnant women.
The aim of this study was to assess the accuracy of the COBAS b101 point-of-care system compared with our local reference laboratory method, for measurement of HbA1c levels in pregnant women.
MATERIALS AND METHODS

Study population
This study was conducted with women enrolled in the Healthy 
Point-of-care system
The COBAS b101 point-of-care system uses a latex agglutination technique. Total haemoglobin is determined initially by mixing a small fraction of the sample with sodium-lauryl-sulfate and the HbA1c level is then measured using a latex agglutination technique. Manufacturer instructions were followed for sample collection, handling of samples, quality control and instrument calibration. 21 The COBAS b101 point-of-care machines were calibrated monthly. For repeatability testing, the COBAS b101 pointof-care system has a coefficient of variation of 2.0% at an HbA1c value of 44 mmol/mol.
21
Reference method
Venous blood samples were tested at the reference laboratory 
Statistical analysis
Statistical analysis was performed using JMP software, ver- Bland-Altman analysis, 23 including mean difference (bias) and 95% limits of agreement. Agreement was also assessed for an HbA1c > 40 mmol/mol, a threshold used for referral in some centres that treat women with pre-diabetes from early pregnancy.
A two-sided P-value of < 0.05 was considered the criterion for statistical significance.
RESULTS
A total of 40 women were included in this study, of whom 22 Laboratory HbA1c levels were normally distributed (mean 35.9, SD 2.0 mmol/mol), and differences between methods were approximately normally distributed (Fig. 1) . The COBAS b101 point-of-care system had a small negative bias com- 
DISCUSSION
This is the first study, to our knowledge, to assess the accuracy of the COBAS b101 HbA1c point-of-care system in pregnant women.
COBAS b101 HbA1c levels were, on average, slightly lower than the laboratory reference values by 1.0 mmol/mol. This is consistent with previous studies in non-pregnant populations that have shown a small negative bias with this device. 19 However, in our F I G U R E 1 Histogram of differences in HbA1c levels between COBAS b101 and laboratory reference method (N = 40). Legend: red solid line is the normal fitted curve (Shapiro-Wilk test P = 0.18). Box plot shows median, interquartile range, 95% confidence limits for the mean (diamond), range and the shortest half (red bracket). point-of-care testing has been shown to improve relationships between patients and their health-care professionals, improve glycaemic control and aid clinician decision making around changes to care. [24] [25] [26] [27] There is limited information about the clinical utility of HbA1c point-of-care testing in pregnant women, although one study found that point-of-care measurements in women diagnosed with gestational diabetes mellitus were predictive of the need for medication. 28 This study has some limitations, including the relatively long recruitment period, which meant that more than one batch of COBAS b101 cartridges were used. We compared capillary and venous whole blood, with potential for matrix effects. We also did not assess other aspects of analytical performance such as precision or repeatability. However, our aim was to assess the accuracy of the COBAS b101 point-of-care system under real-world conditions, as might occur in a community clinical care setting.
F I G U R E 2
The mean HbA1c value in this study was higher than would be expected in the general obstetric population, reflecting the high-risk nature of the HUMBA cohort. For example, in the largest previous study on pregnancy HbA1c, women had a mean (SD) HbA1c of 28.9 (0.5) mmol/mol, 29 considerably lower than the mean (SD) of 35.9 (2.0) mmol/mol observed in our study.
However, this enabled us to assess the accuracy of the COBAS b101 point-of-care system at values close to the clinically significant range.
CONCLUSION
In conclusion, we found that in pregnancy, the COBAS b101 pointof-care system has a small negative bias but only modest point accuracy for HbA1c. For screening of unrecognised diabetes or pre-diabetes in pregnancy, appropriate COBAS b101 HbA1c pointof-care HbA1c thresholds for a negative and positive result are 7 mmol/mol below and 5 mmol/mol above the clinical threshold, respectively. Values between these limits should be confirmed by laboratory testing.
